Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)

PHASE4CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

February 2, 2023

Study Completion Date

January 19, 2024

Conditions
Transcatheter Aortic Valve Replacement
Interventions
DRUG

Vitamin K antagonist or direct oral anticoagulant treatment

"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"

DRUG

Aspirin

"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."

Trial Locations (6)

30029

CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes

30032

Hôpital Privé les Franciscaines, Nîmes

34295

CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier

34960

Clinique du Millénaire, Montpellier

66000

Clinique Saint-Pierre, Perpignan

66046

CH de Perpignan - Hôpital Saint Jean, Perpignan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Centre Hospitalier Universitaire de Nīmes

OTHER